Date de publication: 26 juin 2015
Promoteur – Intermédiaire Financier
UCB SALieu
Description
Financing of UCB New Medicines activities in the fields of neuroscience (Braine-l'Alleud, Belgium) and immunology (Slough, UK) over the period 2015-2017
Objectifs
The project concerns the discovery research, non-clinical developments and early clinical developments, i.e. finding and confirming candidates and progressing them through proof of concept stage in the areas of neurology and immunology.
Commentaires
Professional, Scientific and Technical Activities
Secteur(s)
- Services - Activités spécialisées, scientifiques et techniques
Montant BEI envisagé (montant approximatif)
EUR 150 million
Coût total (montant approximatif)
EUR 426 million
Aspects environnementaux
The project mainly concerns investments in research and development (R&D) that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under Directive 2011/92/EU. Full environmental details will be verified during the appraisal.
Passation des marchés
The promoter has been assessed by the EIB as being a private company not operating in the utilities sector and not having the status of a contracting entity, thus not subject to EU rules on public procurement. However, if, after the project appraisal, the EIB were to conclude that the promoter is after all subject to EU public procurement legislation (i.e. Directive 2004/17/EC), then the Bank would require the promoter to ensure that contracts for the implementation of the project have been/will be tendered in accordance with the relevant applicable EU procurement legislation (Directive 2004/17/EC and Directive 92/13/EEC), with publication of tender notices in the EU Official Journal, as and where required.
Statut
Signé - 15/12/2015
Clause de non-responsabilité
Avant d’être approuvés par le Conseil d’administration et avant la signature des prêts correspondants, les projets font l’objet d’une instruction et de négociations. Par conséquent, les informations et données fournies sur cette page sont indicatives.
Elles sont fournies à des fins de transparence uniquement et ne peuvent être considérées comme représentant la politique officielle de la BEI (voir également les notes explicatives).